{
    "clinical_study": {
        "@rank": "95652", 
        "acronym": "AVA", 
        "arm_group": [
            {
                "arm_group_label": "Teriparatide", 
                "arm_group_type": "Experimental", 
                "description": "20 micrograms (mcg) teriparatide administered subcutaneously (SC) once every day for 6 months.\nDemeclocycline (DEM): Beginning 18 days prior to Randomization: Days 1, 2, 3 and 16, 17, 18: 150 milligram (mg) DEM will be taken orally every 6 hours; Days 4-15: DEM will not be administered.\nTetracycline (TET): Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15 and 19 through 22: TET will not be administered.\nCalcium: Approximately 1000 milligrams per day (mg/day) administered orally.\nVitamin D: Approximately 800 to 1200 International Units per day (IU/day) administered orally."
            }, 
            {
                "arm_group_label": "Denosumab", 
                "arm_group_type": "Active Comparator", 
                "description": "60 mg denosumab administered SC once in 6 months.\nDemeclocycline (DEM): Beginning 18 days prior to Randomization: Days 1, 2, 3 and 16, 17, 18: 150 milligram (mg) DEM will be taken orally every 6 hours; Days 4-15: DEM will not be administered.\nTetracycline (TET): Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15 and 19 through 22: TET will not be administered.\nCalcium: Approximately 1000 mg/day administered orally.\nVitamin D: Approximately 800 to 1200 IU/day administered orally."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine how teriparatide or denosumab affects the bone of\n      postmenopausal women  with osteoporosis after 3 months of treatment, as determined by a bone\n      biopsy sample taken from the iliac crest (upper part of the pelvis)."
        }, 
        "brief_title": "Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoporosis", 
        "condition_browse": {
            "mesh_term": "Osteoporosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ambulatory, postmenopausal women (no vaginal bleeding for at least 2 years prior to\n             screening) with osteoporosis\n\n          -  Bone mineral density (BMD) T-score of at least -2.5 at femoral neck (FN), total hip\n             (TH), or lumbar spine (LS) (L1-L4, with at least 2 evaluable vertebrae), with or\n             without atraumatic fracture after menopause, OR\n\n          -  BMD T-score of at least -1.5 at FN, TH, or LS (L1-L4, with at least 2 evaluable\n             vertebrae), and 1 or more atraumatic fractures after menopause (vertebral or\n             nonvertebral).  Nonvertebral fracture sites allowed are wrist, hip, pelvis, rib,\n             humerus, clavicle, leg (femur, tibia, and fibula, excluding ankle)\n\n          -  Laboratory values for serum calcium, parathyroid hormone (PTH), and alkaline\n             phosphatase must be within the normal reference range\n\n        Exclusion Criteria:\n\n          -  Has an increased risk of osteosarcoma (bone tumor); this includes Paget's disease of\n             bone, a previous bone tumor, or radiation involving the skeleton\n\n          -  Has an allergy or intolerance to teriparatide or denosumab AND/OR is a poor candidate\n             for teriparatide or denosumab treatment (investigator should refer to local product\n             prescribing information)\n\n          -  Has a history of exposure to demeclocycline (DEM) or tetracycline (TET) therapy in\n             the 12 months prior to screening or a known allergy to DEM or TET\n\n          -  Has a condition that could put the participant at additional risk of an adverse event\n             due to the bone biopsy procedure (e.g. bleeding disorder)\n\n          -  Has undergone 2 previous iliac crest bone biopsies (1 in each iliac crest)\n\n          -  Has a 25-hydroxyvitamin D concentration of <10 nanogram per milliliter (ng/mL)\n\n          -  Has currently active or suspected (within 1 year prior to enrollment) diseases that\n             affect bone metabolism, other than osteoporosis (such as renal osteodystrophy,\n             hyperthyroidism, osteomalacia, or hyperparathyroidism)\n\n          -  Has a history of certain cancers within 5 years prior to trial entry\n\n          -  Current or recent (within 1 year prior to enrollment) celiac disease, inflammatory\n             bowel disease, gastric bypass, or other malabsorption syndrome\n\n          -  Has significantly impaired hepatic or renal function\n\n          -  Has had treatment with systemic glucocorticoids in doses \u22655 milligrams/day (mg/day)\n             prednisone/day or equivalent in the 6 calendar months prior to screening\n\n          -  Has taken any intravenous osteoporosis medication\n\n          -  Has had prior treatment with other bisphosphonates and not been off of them for a\n             specific period of time before trial entry\n\n          -  Has participated in any other clinical trial studying teriparatide, PTH, PTH analog,\n             or denosumab, or prior or current treatment with teriparatide, PTH, PTH analog, or\n             denosumab"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "89 Years", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753856", 
            "org_study_id": "14592", 
            "secondary_id": "B3D-US-GHDV"
        }, 
        "intervention": [
            {
                "arm_group_label": "Teriparatide", 
                "description": "Administered SC", 
                "intervention_name": "Teriparatide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "LY333334", 
                    "Forteo", 
                    "Forsteo"
                ]
            }, 
            {
                "arm_group_label": "Denosumab", 
                "description": "Administered SC", 
                "intervention_name": "Denosumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Teriparatide", 
                    "Denosumab"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Demeclocyline", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Teriparatide", 
                    "Denosumab"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Tetracycline", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Teriparatide", 
                    "Denosumab"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Calcium Supplement", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Teriparatide", 
                    "Denosumab"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Vitamin D", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetracycline", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Teriparatide", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Lakewood", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80227"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30501"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68131"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 4E1"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sainte-Foy", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "G1V 3M7"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Anabolism Versus Antiresorption: A Quadruple Labeling Histomorphometry Study to Compare the Mechanism of Action of Teriparatide and Denosumab in Postmenopausal Women With Osteoporosis", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9AM - 5PM  Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline to 3 Months in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Compartment (CC) of Iliac Crest Bone Biopsies", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 3 Months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753856"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline to 3 Months in Mineralizing Surface/Bone Surface (MS/BS) in the Endocortical Compartment, Intracortical Compartment, and Periosteal Compartment of Iliac Crest Bone Biopsies", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 Months"
            }, 
            {
                "measure": "Proportion of Bone with Remodeling-Based Formation and Modeling-Based Formation", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "measure": "Proportion of Overfilled Remodeling Sites", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "measure": "Change from Baseline to 3 Months in Label Length within each Basic Multicellular Unit (BMU)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 Months"
            }, 
            {
                "measure": "Change from Baseline to 3 Months in Mineral Apposition Rate (MAR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 Months"
            }, 
            {
                "measure": "Change from Baseline to 3 Months in Bone Formation Rate (BFR)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 Months"
            }, 
            {
                "measure": "Percent of Single or Double Tetracycline Labels per Bone Surface (sLS/BS), (dLS/BS)", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "measure": "Change from Baseline to 3 Months in Intact Parathyroid Hormone (PTH)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 Months"
            }, 
            {
                "measure": "Change from Baseline to 3 Months in Serum Procollagen Type I N-terminal Propeptide (P1NP)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 Months"
            }, 
            {
                "measure": "Change from Baseline to 3 Months in Serum Osteocalcin", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 Months"
            }, 
            {
                "measure": "Change from Baseline to 3 Months in Serum Carboxyterminal Cross-Linking Telopeptide of Type I Collagen (CTX)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 Months"
            }, 
            {
                "measure": "Activation Frequency (Ac.f )", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "measure": "Adjusted Apposition Rate (Aj.AR)", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "measure": "Number of Samples with Single or Double Tetracycline Labels, Single and Double Labels, or No Tetracycline Labels", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "measure": "Percentage of Osteoid Volume (OV)/Bone Volume (BV)", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "measure": "Percentage of Osteoid Surface (OS)/Bone Surface (BS)", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "measure": "Osteoid Thickness (O.Th)", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "measure": "Wall Thickness (W.Th)", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }, 
            {
                "measure": "Percentage of Eroded Surface/Bone Surface (ES/BS)", 
                "safety_issue": "No", 
                "time_frame": "3 Months"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}